Show simple item record

dc.contributor.authorLeach, Martin O
dc.contributor.authorBrindle, K
dc.contributor.authorEvelhoch, J
dc.contributor.authorGriffiths, John R
dc.contributor.authorHorsman, Michael R
dc.contributor.authorJackson, A
dc.contributor.authorJayson, Gordon C
dc.contributor.authorJudson, Ian R
dc.contributor.authorKnopp, M
dc.contributor.authorMaxwell, Ross J
dc.contributor.authorMcIntyre, D
dc.contributor.authorPadhani, A
dc.contributor.authorPrice, P
dc.contributor.authorRathbone, R
dc.contributor.authorRustin, G
dc.contributor.authorTofts, P
dc.contributor.authorTozer, G
dc.contributor.authorVennart, W
dc.contributor.authorWaterton, John C
dc.contributor.authorWilliams, S
dc.contributor.authorWorkman, Paul
dc.date.accessioned2009-07-22T10:46:22Z
dc.date.available2009-07-22T10:46:22Z
dc.date.issued2005-05-09
dc.identifier.citationThe assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. 2005, 92 (9):1599-610 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid15870830
dc.identifier.doi10.1038/sj.bjc.6602550
dc.identifier.urihttp://hdl.handle.net/10541/74932
dc.description.abstractVascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAntineoplastic Agents
dc.subject.meshClinical Trials as Topic
dc.subject.meshEvaluation Studies as Topic
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshNeoplasms
dc.subject.meshReproducibility of Results
dc.subject.meshTerminology as Topic
dc.titleThe assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. martin.leach@icr.ac.uken
dc.identifier.journalBritish Journal of Canceren
html.description.abstractVascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.


This item appears in the following Collection(s)

Show simple item record